ABSTRACT
A wide variety of drug classes exists that are used to treat osteoporosis and prevent fragility fractures.
Currently, ongoing efforts are being made to develop sophisticated, convenient agents that increase clinical efficacy while minimizing the risk of adverse events. Progress in this emerging field of medicine is rapid, particularly at the speed to which novel targets become effective pharmacologic agents. The challenge will be to most appropriately use these new medications to effectively treat osteoporotic patients.
